Primary reason for not taking medications to prevent <i>Pneumocystis jirovecii</i> pneumonia (PCP) listed by 264 persons who were nonadherent with primary PCP prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

<p>Primary reason for not taking medications to prevent <i>Pneumocystis jirovecii</i> pneumonia (PCP) listed by 264 persons who were nonadherent with primary PCP prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.</p

Characteristics of 1,666 persons with HIV infection prescribed primary prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP), by nonadherence to prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

*<p>Column percentages may not total 100% because of rounding.</p>†<p>P-value <0.05 when comparing persons nonadherent with those adherent to PCP prophylaxis.</p>‡<p>Regions defined by U.S. Census Bureau; for SHAS sites included in this analysis, Northeast comprises NJ, CT, and PA; South comprises GA, MD, FL, SC, DE, and TX; Midwest comprises IL, KS, MI, and MN; and West comprises AZ, CA, CO, NM, and WA.</p>±<p>Other responses included correctional institution, refused to answer, and other responses which did not fit into the listed response categories.</p>§<p>Categories are mutually exclusive.</p>||<p>Defined as answering yes to at least 2 of the CAGE screening questions and reporting alcohol use in the past year.</p

Multivariable analysis of factors associated with nonadherence to primary prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP) – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004.

*<p>In addition to adjusting for variables included in this table, we controlled for region of residence in the U.S. and year of SHAS interview.</p>†<p>P-value<0.05.</p

Characteristics of HIV infected persons interviewed about adherence to currently prescribed antiretroviral therapy, number and proportion of nonadherent respondents, and logistic regression model of factors associated with nonadherence among 5,887 respondents to the Supplement to HIV/AIDS Surveillance Project, 18 US States, 2000 to 2004

<p>ARVT: antiretroviral therapy; PI: protease inhibitor; HAART: Highly active antiretroviral therapy.</p>*<p>Referent group is all other races</p>†<p>Referent group is ≥40 years</p>‡<p>Confidence interval excludes 1.0; lower bound is rounded down to 1.0.</p>§<p>Referent group is all other risks</p>∥<p>Referent group is all other places of residence</p>¶<p>Any use in the 12 months before the interview</p>**<p>Referent group is duration of ARVT treatment <21 months</p>††<p>Referent group is currently prescribed 1–3 drugs</p>‡‡<p>Referent group is any other prescribed regimen</p